Synyogic Lifescience Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.20 M
as on 16-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.42 Cr
as on 16-11-2024
- Revenue -36.70%
(FY 2023)
- Profit -95.79%
(FY 2023)
- Ebitda -80.96%
(FY 2023)
- Net Worth 21.07%
(FY 2023)
- Total Assets 20.19%
(FY 2023)
About Synyogic Lifescience
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹2.42 Cr.
Basavaraju Shreedevi, Basanagoud Patil, and Rajalakshmi serve as directors at the Company.
- CIN/LLPIN
U24230KA2020PTC140238
- Company No.
140238
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Oct 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Synyogic Lifescience?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Basavaraju Shreedevi  | Director | 26-Oct-2020 | Current |
| Basanagoud Patil | Director | 11-Oct-2021 | Current |
| Rajalakshmi | Director | 26-Oct-2020 | Current |
Financial Performance of Synyogic Lifescience.
Synyogic Lifescience Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 36.7% decrease. The company also saw a substantial fall in profitability, with a 95.79% decrease in profit. The company's net worth Soared by an impressive increase of 21.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synyogic Lifescience?
Unlock access to Synyogic Lifescience's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Karnataka Bank Ltd. Creation Date: 27 Sep 2023 | ₹1.40 M | Open |
Others Creation Date: 10 Apr 2023 | ₹1.20 Cr | Open |
Axis Bank Limited Creation Date: 24 Jan 2023 | ₹1.00 Cr | Open |
How Many Employees Work at Synyogic Lifescience?
Unlock and access historical data on people associated with Synyogic Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synyogic Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synyogic Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
